FI65782C - Analogifoerfarande foer framstaellning av terapeutiskt verkande n1-glukofuranosid-6-yl-n3-nitroso-karbamider - Google Patents
Analogifoerfarande foer framstaellning av terapeutiskt verkande n1-glukofuranosid-6-yl-n3-nitroso-karbamider Download PDFInfo
- Publication number
- FI65782C FI65782C FI790556A FI790556A FI65782C FI 65782 C FI65782 C FI 65782C FI 790556 A FI790556 A FI 790556A FI 790556 A FI790556 A FI 790556A FI 65782 C FI65782 C FI 65782C
- Authority
- FI
- Finland
- Prior art keywords
- methyl
- deoxy
- compound
- lower alkyl
- ethyl
- Prior art date
Links
- 235000016709 nutrition Nutrition 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 40
- 125000000217 alkyl group Chemical group 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 10
- 229910052739 hydrogen Inorganic materials 0.000 claims description 8
- 239000001257 hydrogen Substances 0.000 claims description 8
- 229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 claims description 4
- 125000001589 carboacyl group Chemical group 0.000 claims description 4
- 150000002431 hydrogen Chemical class 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 125000001118 alkylidene group Chemical group 0.000 claims description 3
- DHRYBOPROOUCTM-IGORNWKESA-N 3-[(2R)-2-[(2S,3R,4R,5S)-5-ethoxy-3,4-dihydroxyoxolan-2-yl]-2-methoxyethyl]-1-methyl-1-nitrosourea Chemical compound CCO[C@H]1O[C@H]([C@@H](CNC(=O)N(C)N=O)OC)[C@H](O)[C@H]1O DHRYBOPROOUCTM-IGORNWKESA-N 0.000 claims description 2
- 150000001412 amines Chemical class 0.000 claims description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 38
- -1 methoxybenzyl Chemical group 0.000 description 27
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 17
- 241001465754 Metazoa Species 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 239000002253 acid Substances 0.000 description 9
- DRSHXJFUUPIBHX-UHFFFAOYSA-N COc1ccc(cc1)N1N=CC2C=NC(Nc3cc(OC)c(OC)c(OCCCN4CCN(C)CC4)c3)=NC12 Chemical compound COc1ccc(cc1)N1N=CC2C=NC(Nc3cc(OC)c(OC)c(OCCCN4CCN(C)CC4)c3)=NC12 DRSHXJFUUPIBHX-UHFFFAOYSA-N 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 8
- 239000012153 distilled water Substances 0.000 description 7
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 description 7
- 239000007858 starting material Substances 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 5
- 150000001540 azides Chemical class 0.000 description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
- 229910017604 nitric acid Inorganic materials 0.000 description 5
- AVVWPBAENSWJCB-IVMDWMLBSA-N D-glucofuranose Chemical group OC[C@@H](O)[C@H]1OC(O)[C@H](O)[C@H]1O AVVWPBAENSWJCB-IVMDWMLBSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 231100001231 less toxic Toxicity 0.000 description 4
- 208000032839 leukemia Diseases 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 208000007093 Leukemia L1210 Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- ZRKWMRDKSOPRRS-UHFFFAOYSA-N N-Methyl-N-nitrosourea Chemical compound O=NN(C)C(N)=O ZRKWMRDKSOPRRS-UHFFFAOYSA-N 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 208000001382 Experimental Melanoma Diseases 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 150000008065 acid anhydrides Chemical class 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- ZWWCURLKEXEFQT-UHFFFAOYSA-N dinitrogen pentaoxide Chemical compound [O-][N+](=O)O[N+]([O-])=O ZWWCURLKEXEFQT-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 150000002337 glycosamines Chemical class 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 125000000654 isopropylidene group Chemical group C(C)(C)=* 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 2
- 229960001428 mercaptopurine Drugs 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- XCHPVAASELNLDD-QCODTGAPSA-N (2S,3R,4R,5R)-5-[(1R)-2-azido-1-methoxyethyl]-2-ethoxy-4-phenylmethoxyoxolan-3-ol Chemical compound O[C@H]1[C@@H](OCC)O[C@H]([C@@H](CN=[N+]=[N-])OC)[C@@H]1OCC1=CC=CC=C1 XCHPVAASELNLDD-QCODTGAPSA-N 0.000 description 1
- BUEKNSDXIGFJQB-OKNNCHMLSA-N (2S,3R,4R,5S)-2-[(1R)-2-amino-1-methoxyethyl]-5-ethoxyoxolane-3,4-diol Chemical compound CCO[C@H]1O[C@H]([C@@H](CN)OC)[C@H](O)[C@H]1O BUEKNSDXIGFJQB-OKNNCHMLSA-N 0.000 description 1
- DWJZGHGFSSINIX-DRNPWPOYSA-N (3R,4R,5S)-5-[(1S)-2-amino-1,2-dihydroxyethyl]oxolane-2,3,4-triol Chemical compound NC([C@H]([C@@H]1[C@@H]([C@H](C(O)O1)O)O)O)O DWJZGHGFSSINIX-DRNPWPOYSA-N 0.000 description 1
- UOCLXMDMGBRAIB-UHFFFAOYSA-N 1,1,1-trichloroethane Chemical compound CC(Cl)(Cl)Cl UOCLXMDMGBRAIB-UHFFFAOYSA-N 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- NVKGVBZZSJFQLM-UHFFFAOYSA-N 1-(2-chloroethyl)-1-nitrosourea Chemical compound NC(=O)N(N=O)CCCl NVKGVBZZSJFQLM-UHFFFAOYSA-N 0.000 description 1
- ILSUNMIGPQOJMA-IGORNWKESA-N 1-[(2R)-2-[(2S,3R,4R,5S)-5-ethoxy-3,4-dihydroxyoxolan-2-yl]-2-methoxyethyl]-3-methylurea Chemical compound CCO[C@H]1O[C@H]([C@@H](CNC(=O)NC)OC)[C@H](O)[C@H]1O ILSUNMIGPQOJMA-IGORNWKESA-N 0.000 description 1
- ALFIUSMZLZMWRJ-UHFFFAOYSA-N 1-diazo-3-(nitrosomethyl)urea Chemical compound [N-]=[N+]=NC(=O)NCN=O ALFIUSMZLZMWRJ-UHFFFAOYSA-N 0.000 description 1
- APYWVNLMBZUDCS-SOOFDHNKSA-N 1-nitroso-3-[[(2R,3S,4R)-3,4,5-trihydroxyoxolan-2-yl]methyl]urea Chemical class N(=O)NC(NC[C@@H]1[C@H]([C@H](C(O)O1)O)O)=O APYWVNLMBZUDCS-SOOFDHNKSA-N 0.000 description 1
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 1
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000005725 8-Hydroxyquinoline Substances 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 125000003535 D-glucopyranosyl group Chemical group [H]OC([H])([H])[C@@]1([H])OC([H])(*)[C@]([H])(O[H])[C@@]([H])(O[H])[C@]1([H])O[H] 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical group OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000831652 Salinivibrio sharmensis Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- XJKGOXOVPGBEJE-JWISSMICSA-N [(3r,4s,5s)-2-acetyloxy-4-hydroxy-5-[(1r)-1-methoxy-2-[[methyl(nitroso)carbamoyl]amino]ethyl]oxolan-3-yl] acetate Chemical compound O=NN(C)C(=O)NC[C@@H](OC)[C@H]1OC(OC(C)=O)[C@H](OC(C)=O)[C@H]1O XJKGOXOVPGBEJE-JWISSMICSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000719 anti-leukaemic effect Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N carbonic acid monoamide Natural products NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 229920001429 chelating resin Polymers 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000004803 chlorobenzyl group Chemical group 0.000 description 1
- 125000002603 chloroethyl group Chemical group [H]C([*])([H])C([H])([H])Cl 0.000 description 1
- 239000002026 chloroform extract Substances 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 125000006289 hydroxybenzyl group Chemical group 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 125000006178 methyl benzyl group Chemical group 0.000 description 1
- HAMGRBXTJNITHG-UHFFFAOYSA-N methyl isocyanate Chemical compound CN=C=O HAMGRBXTJNITHG-UHFFFAOYSA-N 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 229960003540 oxyquinoline Drugs 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- NMHMNPHRMNGLLB-UHFFFAOYSA-N phloretic acid Chemical compound OC(=O)CCC1=CC=C(O)C=C1 NMHMNPHRMNGLLB-UHFFFAOYSA-N 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- MCJGNVYPOGVAJF-UHFFFAOYSA-N quinolin-8-ol Chemical compound C1=CN=C2C(O)=CC=CC2=C1 MCJGNVYPOGVAJF-UHFFFAOYSA-N 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000000542 sulfonic acid group Chemical group 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
- C07H13/12—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by acids having the group -X-C(=X)-X-, or halides thereof, in which each X means nitrogen, oxygen, sulfur, selenium or tellurium, e.g. carbonic acid, carbamic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH184978 | 1978-02-21 | ||
| CH184978 | 1978-02-21 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| FI790556A7 FI790556A7 (fi) | 1979-08-22 |
| FI65782B FI65782B (fi) | 1984-03-30 |
| FI65782C true FI65782C (fi) | 1984-07-10 |
Family
ID=4220040
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI790556A FI65782C (fi) | 1978-02-21 | 1979-02-19 | Analogifoerfarande foer framstaellning av terapeutiskt verkande n1-glukofuranosid-6-yl-n3-nitroso-karbamider |
Country Status (23)
| Country | Link |
|---|---|
| EP (1) | EP0003788B1 (cs) |
| JP (1) | JPS54122226A (cs) |
| KR (1) | KR820000419B1 (cs) |
| AR (1) | AR227004A1 (cs) |
| AT (1) | AT362389B (cs) |
| AU (1) | AU525495B2 (cs) |
| CA (1) | CA1123825A (cs) |
| CS (2) | CS203946B2 (cs) |
| CY (1) | CY1264A (cs) |
| DE (1) | DE2961524D1 (cs) |
| DK (1) | DK73579A (cs) |
| ES (1) | ES477889A1 (cs) |
| FI (1) | FI65782C (cs) |
| GR (1) | GR74066B (cs) |
| HK (1) | HK96984A (cs) |
| HU (1) | HU179949B (cs) |
| IL (1) | IL56696A (cs) |
| NO (1) | NO146398C (cs) |
| NZ (1) | NZ189703A (cs) |
| PL (2) | PL117325B1 (cs) |
| PT (1) | PT69253A (cs) |
| SU (2) | SU913944A3 (cs) |
| ZA (1) | ZA79803B (cs) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3157684A (en) * | 1961-02-13 | 1964-11-17 | Atomic Energy Authority Uk | Tritiated-2-methyl-naphthaquinol-(1, 4)-diphosphoric acids |
| JPS5681596A (en) * | 1979-12-07 | 1981-07-03 | Tokyo Tanabe Co Ltd | Glucopyranose-nitrosourea derivative, carcinostatic agent consisting of the same and preparation |
| US4387220A (en) * | 1980-11-05 | 1983-06-07 | The Nissin Sugar Manufacturing Co., Ltd. | Nitrosourea derivatives of sucrose |
| FR2614304A1 (fr) * | 1987-04-22 | 1988-10-28 | Sanofi Sa | Derives de nitrosourees, leur nouveau procede de preparation et leurs applications therapeutiques. |
| PL233967B1 (pl) | 2016-03-24 | 2019-12-31 | Naturlen Spólka Z Ograniczona Odpowiedzialnoscia | Sposób wytwarzania materiału opatrunkowego z zastosowaniem włókien lnianych oraz materiał opatrunkowy z zastosowaniem włókien lnianych |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5175072A (ja) * | 1974-12-18 | 1976-06-29 | Tokyo Tanabe Co | Ribofuranoozunonitorosokarubamirujudotaino seizoho |
| JPS52151125A (en) * | 1976-05-18 | 1977-12-15 | Tokyo Tanabe Co | Process for manufacturing chloroethylnitrosourea derivatives of alkylglucopyranose |
| FI65781C (fi) * | 1977-06-15 | 1984-07-10 | Ciba Geigy Ag | Analogifoerfarande foer framstaellning av terapeutiskt verkande n1-glukofuranosid-6-yl-n3-nitroso-urinaemnen |
-
1979
- 1979-02-12 DE DE7979100400T patent/DE2961524D1/de not_active Expired
- 1979-02-12 EP EP79100400A patent/EP0003788B1/de not_active Expired
- 1979-02-12 CY CY1264A patent/CY1264A/xx unknown
- 1979-02-19 CA CA321,736A patent/CA1123825A/en not_active Expired
- 1979-02-19 GR GR58402A patent/GR74066B/el unknown
- 1979-02-19 FI FI790556A patent/FI65782C/fi not_active IP Right Cessation
- 1979-02-19 IL IL56696A patent/IL56696A/xx unknown
- 1979-02-20 NZ NZ189703A patent/NZ189703A/xx unknown
- 1979-02-20 CS CS791135A patent/CS203946B2/cs unknown
- 1979-02-20 ES ES477889A patent/ES477889A1/es not_active Expired
- 1979-02-20 SU SU792734802A patent/SU913944A3/ru active
- 1979-02-20 HU HU79CI1915A patent/HU179949B/hu unknown
- 1979-02-20 NO NO790564A patent/NO146398C/no unknown
- 1979-02-20 ZA ZA79803A patent/ZA79803B/xx unknown
- 1979-02-20 PT PT69253A patent/PT69253A/pt unknown
- 1979-02-20 KR KR7900515A patent/KR820000419B1/ko not_active Expired
- 1979-02-20 AT AT128979A patent/AT362389B/de not_active IP Right Cessation
- 1979-02-20 DK DK73579A patent/DK73579A/da not_active Application Discontinuation
- 1979-02-20 AU AU44393/79A patent/AU525495B2/en not_active Ceased
- 1979-02-20 CS CS797793A patent/CS203947B2/cs unknown
- 1979-02-21 PL PL1979213595A patent/PL117325B1/pl unknown
- 1979-02-21 AR AR275566A patent/AR227004A1/es active
- 1979-02-21 PL PL1979219884A patent/PL117894B1/pl unknown
- 1979-02-21 JP JP1852679A patent/JPS54122226A/ja active Pending
- 1979-12-11 SU SU792853127A patent/SU1028250A3/ru active
-
1984
- 1984-12-13 HK HK969/84A patent/HK96984A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AT362389B (de) | 1981-05-11 |
| FI65782B (fi) | 1984-03-30 |
| DK73579A (da) | 1979-08-22 |
| CS203947B2 (en) | 1981-03-31 |
| NO146398B (no) | 1982-06-14 |
| HK96984A (en) | 1984-12-21 |
| DE2961524D1 (en) | 1982-02-04 |
| CY1264A (en) | 1984-11-23 |
| NO146398C (no) | 1982-09-22 |
| EP0003788A2 (de) | 1979-09-05 |
| NZ189703A (en) | 1981-07-13 |
| ES477889A1 (es) | 1979-08-01 |
| ZA79803B (en) | 1980-10-29 |
| SU913944A3 (en) | 1982-03-15 |
| PL213595A2 (cs) | 1980-04-08 |
| PL117894B1 (en) | 1981-08-31 |
| CA1123825A (en) | 1982-05-18 |
| CS203946B2 (en) | 1981-03-31 |
| IL56696A (en) | 1982-08-31 |
| FI790556A7 (fi) | 1979-08-22 |
| HU179949B (en) | 1983-01-28 |
| PL117325B1 (en) | 1981-07-31 |
| EP0003788B1 (de) | 1981-12-09 |
| ATA128979A (de) | 1980-10-15 |
| AU525495B2 (en) | 1982-11-11 |
| GR74066B (cs) | 1984-06-06 |
| KR820000419B1 (ko) | 1982-04-01 |
| AU4439379A (en) | 1979-08-30 |
| JPS54122226A (en) | 1979-09-21 |
| NO790564L (no) | 1979-08-22 |
| PL219884A1 (cs) | 1980-07-14 |
| AR227004A1 (es) | 1982-09-15 |
| PT69253A (de) | 1979-03-01 |
| IL56696A0 (en) | 1979-05-31 |
| SU1028250A3 (ru) | 1983-07-07 |
| EP0003788A3 (en) | 1979-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI77870C (fi) | Foerfarande foer framstaellning av antivirala difluorsubstituerade nukleosider och difluorkolhydrater anvaendbara som mellanprodukter vid foerfarandet. | |
| KR890003426B1 (ko) | 뉴클레오시드 및 이의 제조방법 | |
| SU682134A3 (ru) | Способ получени производных эритромицина или их солей | |
| US4314998A (en) | 6-Deoxyglucosamine-peptide derivatives, their production and use | |
| SI9620099A (sl) | Diglikozilirani 1,2-dioli kot mimetiki sialil-Lewis X in sialil-Lewis A | |
| US8399634B2 (en) | Reagents and methods for preparing LPS antagonist B1287 and stereoisomers thereof | |
| US4372948A (en) | Derivative of saccharide and physiologically active agent containing the same | |
| NO166792B (no) | Sialinsyrederivater og bindemiddel inneholdende slike. | |
| Schaumberg et al. | 2'-Chloropentostatin, a new inhibitor of adenosine deaminase | |
| FI65782C (fi) | Analogifoerfarande foer framstaellning av terapeutiskt verkande n1-glukofuranosid-6-yl-n3-nitroso-karbamider | |
| Ikehara et al. | Studies of Nucleosides and Nucleotides. XXIII. A Versatile Method for Replacement of 6-Hydroxyl Group of Purine Nucleoside. | |
| FI65781C (fi) | Analogifoerfarande foer framstaellning av terapeutiskt verkande n1-glukofuranosid-6-yl-n3-nitroso-urinaemnen | |
| Cao et al. | Scope and applications of “active and latent” thioglycosyl donors. Part 4 | |
| Van Boom et al. | Synthesis of a Conformationally Constrained Heparin‐like Pentasaccharide | |
| FR2499577A1 (fr) | Nouvelles 1-(2-chloroethyl)-1-nitrosourees-3-substituees par un reste de sucre, utiles notamment comme agents antitumoraux et leur procede de preparation | |
| Prudhomme et al. | Semisynthesis of A23187 (Calcimycin) analogs II. Introduction of a methyl group on the benzoxazole ring | |
| Cristófalo et al. | Synthesis of 2-Propynyl 2-Acetamido-sss3, 4, 6-Tri-O-Acetyl-2-Deoxy-1-Thio-β-d-Glucopyranoside, 2-Propynyl 3, 4, 6-Tri-O-Acetyl-2-Deoxy-2-Phthalimido-1-Thio-β-d-Glucopyranoside and Their 2-(2-Propynyloxyethoxy) ethyl Analogs | |
| US4112075A (en) | Furanose-O-pyridylcarboxylic acid esters | |
| EP1996603B1 (en) | Lipid a antagonists with anti-septic shock, anti-inflammatory, anti-ischemia and analgesic activity | |
| Reist et al. | Synthesis of 4-Acetamido-1, 2, 3, 5-tetra-O-acetyl-4-deoxy-D-ribofuranose. A Pyrrolidine Sugar1-3 | |
| US4675390A (en) | 2-deoxypentose derivatives | |
| Cech et al. | Fluorination of 6-methyluracil and its nucleosides | |
| Gent et al. | The allyl ether as a protecting group in carbohydrate chemistry. Part IV. The 2-methylallyl ether group | |
| GB1596007A (en) | Non-glycosidic theophylline-sugar compounds and pharmaceutical compositions containing them | |
| EP0063481B1 (en) | Water-soluble antitumor, antiviral and immunosuppressant compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM | Patent lapsed |
Owner name: CIBA-GEIGY AG |